On 1 August 2024, Xbrane Biopharma announced that it will regain full rights to XcimzaneTM (BIIB801) biosimilar to UCB’s Cimzia® (certolizumab pegol) for rheumatoid arthritis and psoriasis. Xbrane and Biogen had entered into a commercialisation and licensing agreement in February 2022 under which Biogen was granted commercialisation rights to the Xbrane-developed XcimzaneTM. That agreement has now been terminated.
According to Xbrane, BIIB801 is the only certolizumab pegol biosimilar candidate under development globally. Xbrane reports that it has begun an out-licensing process to identify a new partner.
In October 2021, Xbrane entered into an agreement with AGC Biologics to manufacture Xcimzane™ for clinical development.